Immunotherapy of histiocytosis-X.
This article focuses on the interaction of histiocytosis-X and the immunotherapeutic agent, suppression. Studies with this and other agents have presented us with invaluable insights into the nature of histiocytosis-X.
Osband
M E
ME
Boston City Hospital, Massachusetts.
D000818:Animals; D002986:Clinical Trials as Topic; D004311:Double-Blind Method; D006646:Histiocytosis, Langerhans-Cell / Q000188:drug therapy* / Q000276:immunology; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use*; D007801:Langerhans Cells / Q000276:immunology; D011897:Random Allocation; D013951:Thymus Hormones / Q000276:immunology / Q000627:therapeutic use*
D007166:Immunosuppressive Agents; D013951:Thymus Hormones; C053750:suppressin